Back to Awarded Treatment Trials
Awarded Trial: 99-128
Grant ID
99-128
Illness
Bipolar Disorder
Primary Drug/Intervention
Pramipexole
Primary Dosage
Mean dose = 1.7 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Goldberg
Sample Size
60
Duration of Study Period for Each Subject
6 weeks
Outcome Measurements
HDRS, CGI
Results
Twenty-two patients with bipolar depression received the anti-parkison?s drug pramipexole or placebo. Sixty-seven percent of patients receiving the drug had a 50% reduction in symptoms, whereas only 20% of patients receiving placebo improved to a similar degree.
Publication
Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. American Journal of Psychiatry 2004;161:564-566.
Link
http://www.ncbi.nlm.nih.gov/pubmed/14992985
PI Name
Joseph Goldberg
Degree
MD
Center
Payne Whitney Clinic, New York Presbyterian Hospital
Institution
Cornell University Medical College
Address
525 E. 68th Street, Box 140
City or Town
New York
State or Province
NY
Zip or Postal Code
10021
Country
USA
Email Address
jfgoldbe@mail.med.cornell.edu